Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells $3,055,500.00 in Stock

NewAmsterdam Pharma (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 150,000 shares of the business’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares in the company, valued at $305,550. This represents a 90.91 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $23.80 on Friday. The company has a market cap of $2.20 billion, a P/E ratio of -9.15 and a beta of -0.04. NewAmsterdam Pharma has a fifty-two week low of $15.19 and a fifty-two week high of $27.29. The stock has a 50 day simple moving average of $22.24 and a two-hundred day simple moving average of $20.43.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. On average, research analysts predict that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on NAMS shares. Royal Bank of Canada restated an “outperform” rating and set a $40.00 price target on shares of NewAmsterdam Pharma in a report on Friday, January 24th. HC Wainwright restated a “buy” rating and issued a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Needham & Company LLC cut their price target on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Finally, Scotiabank increased their price objective on NewAmsterdam Pharma from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Thursday, February 27th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $43.80.

Institutional Trading of NewAmsterdam Pharma

Several large investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in NewAmsterdam Pharma in the fourth quarter worth approximately $50,000. Frazier Life Sciences Management L.P. grew its position in NewAmsterdam Pharma by 23.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company’s stock valued at $409,052,000 after purchasing an additional 3,061,224 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in NewAmsterdam Pharma by 6.0% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 253,571 shares of the company’s stock valued at $6,517,000 after purchasing an additional 14,288 shares in the last quarter. Voloridge Investment Management LLC acquired a new position in NewAmsterdam Pharma during the fourth quarter worth $721,000. Finally, Woodline Partners LP lifted its stake in shares of NewAmsterdam Pharma by 108.7% in the fourth quarter. Woodline Partners LP now owns 2,430,782 shares of the company’s stock valued at $62,471,000 after buying an additional 1,266,105 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.